CD4 and type 1 diabetes mellitus: Endogenous IL-2 production in response to anti-CD3 treatment was reported in the original preclinical NOD mouse study [60], and plasma IL-2 was increased in a portion of participants in the clinical trials of teplizumab in T1D, accompanied by an increase of CD25+CD4+ T cells [61].